837 related articles for article (PubMed ID: 24092345)
41. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
[TBL] [Abstract][Full Text] [Related]
42. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G
Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687
[TBL] [Abstract][Full Text] [Related]
43. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
[TBL] [Abstract][Full Text] [Related]
44. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Gratsianskaya SE; Valieva ZS; Martynyuk TV
Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
[TBL] [Abstract][Full Text] [Related]
45. A Hopeful Prospect of Riociguat as a Soluble Guanylate Cyclase Stimulator for Management of Pressure Ulcers.
Azadi S; Ashrafi H; Azadi A
Curr Drug Discov Technol; 2018; 15(1):20-23. PubMed ID: 28914189
[TBL] [Abstract][Full Text] [Related]
46. Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension.
Amirjanians M; Egemnazarov B; Sydykov A; Kojonazarov B; Brandes R; Luitel H; Pradhan K; Stasch JP; Redlich G; Weissmann N; Grimminger F; Seeger W; Ghofrani H; Schermuly R
Oncotarget; 2017 May; 8(18):29613-29624. PubMed ID: 28410199
[TBL] [Abstract][Full Text] [Related]
47. Soluble guanylate cyclase modulators in heart failure.
Mitrovic V; Jovanovic A; Lehinant S
Curr Heart Fail Rep; 2011 Mar; 8(1):38-44. PubMed ID: 21207207
[TBL] [Abstract][Full Text] [Related]
48. Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs.
Næsheim T; How OJ; Myrmel T
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):75-87. PubMed ID: 32662299
[TBL] [Abstract][Full Text] [Related]
49. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
50. Mechanism of relaxation and interaction with nitric oxide of the soluble guanylate cyclase stimulator BAY 41-2272 in mouse gastric fundus and colon.
Cosyns SM; Lefebvre RA
Eur J Pharmacol; 2012 Jul; 686(1-3):104-15. PubMed ID: 22575520
[TBL] [Abstract][Full Text] [Related]
51. Soluble guanylate cyclase stimulator riociguat improves spatial memory in mice via peripheral mechanisms.
Nelissen E; van Hagen BTJ; Argyrousi EK; van Goethem NP; Heckman PRA; Paes D; Mulder-Jongen DAJ; Ramaekers JG; Blokland A; Schmidt HHHW; Prickaerts J
Neurosci Lett; 2022 Sep; 788():136840. PubMed ID: 35985509
[TBL] [Abstract][Full Text] [Related]
52. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
53. The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.
Zheng X; Zheng W; Xiong B; Huang J
Medicine (Baltimore); 2018 Oct; 97(41):e12709. PubMed ID: 30313068
[TBL] [Abstract][Full Text] [Related]
54. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop BM
Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
[TBL] [Abstract][Full Text] [Related]
55. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.
Geschka S; Kretschmer A; Sharkovska Y; Evgenov OV; Lawrenz B; Hucke A; Hocher B; Stasch JP
PLoS One; 2011; 6(7):e21853. PubMed ID: 21789188
[TBL] [Abstract][Full Text] [Related]
56. Riociguat for pulmonary hypertension.
Ghofrani HA; Voswinckel R; Gall H; Schermuly R; Weissmann N; Seeger W; Grimminger F
Future Cardiol; 2010 Mar; 6(2):155-66. PubMed ID: 20230258
[TBL] [Abstract][Full Text] [Related]
57. Modern view on the place of riociguat in the treatment of pulmonary hypertension.
Valieva ZS; Taran IN; Martynyuk TV; Chazova IY
Ter Arkh; 2018 Apr; 90(4):55-59. PubMed ID: 30701875
[TBL] [Abstract][Full Text] [Related]
58. Riociguat for the treatment of pulmonary hypertension: a safety evaluation.
Binder C; Zotter-Tufaro C; Bonderman D
Expert Opin Drug Saf; 2016 Dec; 15(12):1671-1677. PubMed ID: 27750459
[TBL] [Abstract][Full Text] [Related]
59. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
Ghio S; Bonderman D; Felix SB; Ghofrani HA; Michelakis ED; Mitrovic V; Oudiz RJ; Frey R; Roessig L; Semigran MJ
Eur J Heart Fail; 2012 Aug; 14(8):946-53. PubMed ID: 22719060
[TBL] [Abstract][Full Text] [Related]
60. Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension.
Wunder F; Stasch JP; Knorr A; Mondritzki T; Brockschnieder D; Becker-Pelster EM; Sandner P; Tinel H; Redlich G; Hartung IV; Vakalopoulos A; Follmann M
Br J Pharmacol; 2023 Oct; 180(19):2500-2513. PubMed ID: 37170767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
